-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250

Benzinga·07/24/2026 15:08:36
Listen to the news
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.